Zhang B, Cai Y, Zhang Q
Department of Breast Cancer, Liaoning Province Tumor Hospital, Shenyang.
Zhonghua Zhong Liu Za Zhi. 1997 Jul;19(4):277-80.
To evaluate the long-term therapeutic results of preoperative chemotherapy for operable breast cancer.
Patients were divided into preoperative chemotherapy group (group A, 253 cases) and postoperative adjuvant chemotherapy group(group B, 284 cases). The group A patients received preoperative chemotherapy for 4 weeks, followed by radical operation two weeks after chemotherapy. Postoperative adjuvant chemotherapy began within 2 weeks after surgery, with the same chemotherapeutic regimen for 6 or more cycles in both groups.
(1) The 5-year overall survival rate (OS) and disease-free survival rate(DFS) were 59% and 54.9%, respectively, for group A in stage III, which were higher than those of group B(28.3% and 20.8%, P < 0.05). (2) For group A in stage II and III, the 8-year OS were 81.4% and 46.9%, and DFS were 76.3% and 40.6%, respectively, which were higher than those of group B(OS: 67.4% and 20.7%, DFS: 62.9% and 13.3%, P < 0.05). (3) The 5-year and 8-year OS were higher for group A than those for group B in patients with T3, T4 or positive nodes > or = 4, (P < 0.05).
The results show that preoperative chemotherapy can improve the short- and long-term survival of patients with operable, stage III breast cancer and long-term survival of patients with stage II breast cancer.
评估可手术乳腺癌术前化疗的长期治疗效果。
患者分为术前化疗组（A组，253例）和术后辅助化疗组（B组，284例）。A组患者接受4周术前化疗，化疗后2周进行根治性手术。术后辅助化疗在术后2周内开始，两组化疗方案相同，均进行6个或更多周期。
（1）Ⅲ期A组5年总生存率（OS）和无病生存率（DFS）分别为59%和54.9%，高于B组（28.3%和20.8%，P<0.05）。（2）Ⅱ期和Ⅲ期A组8年OS分别为81.4%和46.9%，DFS分别为76.3%和40.6%，高于B组（OS：67.4%和20.7%，DFS：62.9%和13.3%，P<0.05）。（3）T3、T4或阳性淋巴结≥4个的患者中，A组5年和8年OS高于B组（P<0.05）。
结果表明，术前化疗可提高可手术Ⅲ期乳腺癌患者的短期和长期生存率以及Ⅱ期乳腺癌患者的长期生存率。
